Pathology News is excited to announce the expansion of our partnership with Digital Pathology Place, a leading provider of digital pathology solutions. Our partnership will now include the promotion of Digital Pathology Place's educational content, Pathology 101 for Tissue Image Analysis.
Aiosyn, a medical software company that develops AI-powered pathology solutions, has been awarded a 1,6M € Eurostars grant together with Pathomation and Radboud university medical center to accelerate the development of a Kidney-AI algorithm suite. The AWAKE (AI-powered Workflow for Assisted KidnEy diagnostics) project will bring the first AI-powered solution for renal diagnostics and clinical trials to market. AWAKE will also advance the Pathomation software suite with the goal to develop an open and vendor-neutral digital pathology software platform with multiple AI modules such as workflow and clinical-grade diagnostic tools.
Abstract: Spatial omics is an emerging field that combines high-resolution imaging and sequencing technologies to map the spatial distribution of molecules within tissues. By integrating spatial omics techniques into digital pathology, researchers are gaining unprecedented insights into the molecular mechanisms underlying various diseases, which could lead to improved diagnostics, prognostics, and personalized treatments. This article will explore the role of spatial omics in digital [...]
The first NHS Trust of the PathLAKE Plus consortium has signed an individual contract to adopt Aiforia PD-L1 AI model for lung cancer in clinical diagnostics. The duration of the contract is three years, with a possible three-year extension.
Leica Biosystems today announced the US Food and Drug Administration (FDA) 510(k) clearance of the BOND MMR Antibody Panel, providing customers with a high-performing IHC Mismatch Repair (MMR) option when screening colorectal cancer patients for the identification of probable Lynch syndrome.
What do cancer and climate change have in common? Both are very serious problems and in both, machine learning (ML) and artificial intelligence (AI) can be used to support potential solutions. Even though these AI applications may seem very different the ML methods used to support work on both problems are very similar.
Born from a collaboration between Owkin and Gustave Roussy, Europe's leading cancer hospital, PortrAIt will see research hospitals and pathology labs across France working with French technology leaders to develop and deploy new digital pathology AI tools to improve cancer treatment. The project aims to build at least 15 AI-based tools to improve the diagnosis of cancer, the discovery of new treatment biomarkers and the prediction of patient outcomes in hospitals across France.
Corista, a leading provider of clinical, research and educational digital pathology image management solutions, and Qritive, a leading developer of artificial intelligence (AI)-powered cancer computational modules, are announcing a new partnership in digital pathology. Through the partnership, Corista’s DP3® image management platform and Qritive’s artificial intelligence modules will be integrated to help pathologist’s focus their time towards more complex case work. The combined solution enables computational modules to screen for prostate and colon cancers, quantify IHC markers, and detect lymph node metastasis.With this integrated solution, pathologists will be able to increase their efficiency by prioritizing and grading specific cases, while improving the detection of difficult to diagnose cancers. This enhanced digital pathology workflow will allow for pre-reviewed AI analysis of digital pathology images utilizing any whole slide image scanning device and laboratory information system (LIS).Corista’s industry-leading clinical image management system DP3 is DICOM-compliant, enables voice collaborations, remote case review, global consults, integrated image analysis with both in-house and commercially available systems, and a proprietary LIS Connector— all in one platform. Combined with Qritive’s AI modules for prostate, colon, lymph metastasis, and the quantification of IHC markers, the integrated solution will support pathologists in making the highest quality diagnoses, while freeing their time for the review of challenging cases.“Qritive is pushing new frontiers in pathology with Al that is safe, adaptable, and reliable for clinical use,” said Aneesh Sathe, CEO and Co-founder of Qritive. Mr. Sathe continued to state “Corista’s image management system combined with the assistive power of Qritive’s AI modules is the ideal workbench for pathologists to conduct computational modules with ease, consistency, and precision.”“Corista’s DP3 platform was built in conjunction with some of the most respected pathology centers at leading medical centers in the US, specifically for clinical-grade pathology use cases. Today, DP3 is the digital pathology platform of choice for many of the largest medical centers across the country”, said Liz Wingard, CEO and Co-founder of Corista. “Our partnership with Qritive will advance the use of artificial intelligence applications to support the growing demands on pathologists to keep up with the pace of their workloads, and the challenges of cancer diagnosis.”About CoristaCorista’s DP3® digital pathology image management system is unlocking the scale, reach and utility of digital pathology for physicians, scientists, and researchers around the world. The industry leading, only pathology-focused software with DICOM compliance and ability to natively read every scanner’s image format, DP3 integrates universal image access with a full suite of workflow, voice collaboration, search and integrated image analysis functionality. DP3’s scalable and secure platform is accessible from any web-enabled device, putting the power of universal access and analysis together with proven LIS integration. DP3 is the industry’s most comprehensive digital pathology platform and the winner of Frost & Sullivan’s Product Innovation Award. For more information visit www.corista.comAbout QritiveWith operations in USA, Singapore, and India, Qritive is a breakthrough Artificial Intelligence (AI) solution developer that is advancing digital pathology for cancer diagnosis, enhancing imaging accuracy and improving health outcomes. Qritive expands on deep-learning technology to provide automated interpretation of pathology tests for time and resource-strapped medical imaging professionals – enabling faster diagnosis and reducing time to treatment for patients. Its AI-powered solutions empower healthcare professionals across the globe to operate collaboratively at the peak of their performance despite complexity and distance. For more information, visit us here.SOURCE: Corista
One of the most common misconceptions about pathology is that it is limited to laboratory work. While it is true that pathologists spend a significant amount of time in the lab, they are also involved in other areas of medicine. For example, pathologists play a critical role in diagnosing diseases and determining the appropriate treatment plan. They may also work in hospital settings, providing consultations on complex cases or serving as medical directors of clinical laboratories.
Small mammals such as gerbils are becoming increasingly popular as pets and today’s owners have a greater understanding of the environmental, nutritional, and behavioural needs of these creatures. This is reflected in increasing numbers of published papers and data that are now available for small mammals although, unlike other rodent species, there is relatively little information about naturally occurring diseases in pet gerbils. Small mammals have their own unique perspective on the common lesions, even amongst different subspecies. Nevertheless, it is still possible to apply “first principles pathology” to investigate lesions and form an appropriate differential list, just as we do for other domestic species.
